US Patent Family Members and Approved Drugs for United States of America Patent: 2017081326

Try a free trial

See Plans and Pricing

« Back to Dashboard

US Patent Family Members and Approved Drugs for United States of America Patent: US2017081326

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.

Glossary

Subscribe to access the full database, or try a Free Trial
US Patent Number	Estimated Patent Expiration	Generic Name	US Applicant	US Tradename
➤ Sign Up	2035-09-21	asparaginase	Merck	ELSPAR
➤ Sign Up	2035-09-21	rituximab	Genentech	RITUXAN
➤ Sign Up	2035-09-21	trastuzumab	Genentech	HERCEPTIN
➤ Sign Up	2035-09-21	alemtuzumab	Genzyme	CAMPATH
US Patent Number	Estimated Patent Expiration	Generic Name	US Applicant	US Tradename

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.